Patient Reported Outcomes in Patients With Chronic Migraine Treated With BOTOX®
NCT ID: NCT02502123
Last Updated: 2019-04-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
215 participants
OBSERVATIONAL
2015-07-02
2019-01-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Observational Study of BOTOX® as Headache Prophylaxis for Chronic Migraine
NCT01686581
BOTOX® Prophylaxis in Patients With Chronic Migraine
NCT01432379
A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With Chronic Migraine
NCT01516892
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine
NCT05028569
A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine
NCT01662492
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
OnabotulinumtoxinA (BOTOX®)
Patients diagnosed with chronic migraine headache treated with BOTOX® as standard of care in clinical practice. No intervention was administered in this study.
No Intervention
No intervention was administered in this study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No Intervention
No intervention was administered in this study.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patient who is currently taking or planning on taking opioid-containing products, barbiturates or combination for acute headache or pain condition.
* Treatment with any other botulinum toxin product for any condition within 3 months of the screening visit.
* Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis or any other significant disease that might interfere with neuromuscular function.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Allergan
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Goran Davidoic
Role: STUDY_DIRECTOR
Allergan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Foothills Medical Centre
Calgary, Alberta, Canada
Hys Medical Centre
Edmonton, Alberta, Canada
Bayside Medical Centre
Brentwood Bay, British Columbia, Canada
Jeff Oyler
Kamloops, British Columbia, Canada
Dhawan Medical Corporation Medical Clinic
Vancouver, British Columbia, Canada
May Ong-Lam
Vancouver, British Columbia, Canada
Island Neurology
Victoria, British Columbia, Canada
Hamilton Headache Clinic
Hamilton, Ontario, Canada
The Shapero Markham Headache and Pain Treatment Centre
Markham, Ontario, Canada
Pain Care Clinics
Mississauga, Ontario, Canada
Toronto Headache & Pain Centre
North York, Ontario, Canada
Hany Demian
Oakville, Ontario, Canada
Nepean Medical Centre
Ottawa, Ontario, Canada
Centre de traitement neurologique
Monthreal, Quebec, Canada
Clinic Greene Avenue
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GMA-CAN-NEU-0336
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.